By Fineline Cube 
On August 21, 2025, Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266), a China-based company, announced that the National Medical Products Administration (NMPA) has approved its clinical trial for ZG005 in combination with gecacitinib hydrochloride tablets and chemotherapy for advanced solid tumors.
ZG005: Dual-Targeting Bispecific Antibody
ZG005 is a recombinant humanized anti-PD-1/TIGIT bispecific antibody, classified as a Class 1 drug. It has the potential to treat various solid tumors by simultaneously blocking PD-1 and TIGIT. This dual action promotes T cell activation and proliferation while enhancing the immune system’s ability to kill tumor cells.
Gecacitinib: Innovative Dual Inhibitor
Gecacitinib, a novel JAK and ACVR1 dual inhibitor independently developed by Suzhou Zelgen, holds independent intellectual property rights. Its New Drug Application (NDA) for treating intermediate- and high-risk myelofibrosis has been approved by the NMPA, marking it as the first domestically developed innovative JAK inhibitor for this indication. Additionally, the NDA for treating severe alopecia areata has been accepted by the NMPA.-Fineline Info & Tech